 The purpose of this study is to characterize the hematological response rate, as well as other parameters of efficacy and safety induced by tipifarnib in patients with high-risk myelodysplastic syndrome MDS. Tipifarnib belongs to a class of drugs called Farnesyl Transferase Inhibitors FTI. It blocks proteins that make cancer cells grow. 